Table 4.

Adverse events.

	Evolocumab (n = 60)	SOC (n = 60)	p a
Any adverse event	5	6	0.75
Serious adverse event	0	1 (3.33%)	0.32
Events of special interest
ALT or AST >3×ULN	2 (3.33%)	2 (3.33%)	1.00
General allergic reaction	0	0	-
Local injection site reaction	2 (3.33%)	—	—
Neurocognitive event	1 (1.67%)	1 (1.67%)	1.00
Musculoskeletal pain	0	1 (1.67%)	0.32
Cerebrovascular event	0	1 (3.33%)	0.32
Cerebral hemorrhage	0	1 (3.33%)	0.32
Myocardial infarction	0	0	—
Cardiovascular death	0	0	—
All-cause death	0	0	—

SOC, standard of care; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

^aFisher exact test.